STOCK TITAN

SIGYN THERAPEUTICS INC - SIGY STOCK NEWS

Welcome to our dedicated page for SIGYN THERAPEUTICS news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on SIGYN THERAPEUTICS stock.

Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a development-stage medical technology company based in San Diego, California. The company is pioneering blood purification technologies to address pathogen-associated inflammatory disorders, which are not effectively treated by traditional drug therapies.

Sigyn's flagship product, Sigyn Therapy™, targets a range of severe medical conditions including endotoxemia, sepsis, community-acquired pneumonia, and infections by drug-resistant bacteria and viruses. The initial clinical focus is on end-stage renal disease (ESRD) patients suffering from endotoxemia, a prevalent condition linked to increased mortality.

Further broadening its innovative portfolio, Sigyn Therapeutics is also developing ImmunePrep™, ChemoPrep™, and ChemoPure™. ImmunePrep™ aims to improve the efficacy of immunotherapeutic antibodies, a market projected to grow exponentially. ChemoPrep™ is designed to enhance the delivery and reduce the toxicity of chemotherapy, addressing a crucial need as less than 5% of chemotherapy reaches the tumor site. ChemoPure™ further mitigates chemotherapy toxicity by extracting off-target drugs from the bloodstream post-treatment.

Despite its development-stage status, Sigyn has demonstrated promising in vitro results, reducing the prevalence of multiple pathogen and inflammatory targets in human blood plasma. The company has initiated steps to begin first-in-human studies and is in the process of finalizing study protocols for Sigyn Therapy™ in ESRD patients.

On the financial front, Sigyn reported a net loss of approximately $4.1 million for the year ending December 31, 2023, indicating its commitment to research and development. The company recently completed a 1-for-40 reverse stock split, a strategic move aimed at meeting Nasdaq listing requirements.

Sigyn Therapeutics continues to advance its mission, positioning itself as a leader in the medical technology field with a comprehensive pipeline aimed at improving patient outcomes and addressing unmet medical needs.

Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTCQB: SIGY) reported its Q2 2022 financial results, showing a net loss of approximately $666,000, or $0.02 per share. This compares to a net loss of $650,000 in Q2 2021. The company announced the successful completion of in vivo animal studies for its Sigyn Therapy, aimed at treating life-threatening infections and inflammatory disorders. Additionally, it appointed Jeremy Ferrell as CFO and established a Scientific Advisory Board. Sigyn's stock graduated to the OTCQB Venture Exchange, and it continues pursuing a major exchange listing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTCQB: SIGY) has commenced trading on the OTCQB® Venture Exchange, moving from the OTC Pink Market. This transition aligns with the company's goal of listing on a major exchange. Sigyn Therapeutics is advancing Sigyn Therapy™, a blood purification technology designed to extract infectious pathogens and inflammatory mediators. The technology targets conditions such as sepsis and end-stage renal disease. CEO Jim Joyce emphasized the significance of this development as part of the company's evolution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
Rhea-AI Summary

Sigyn Therapeutics (OTC: SIGY) has appointed Dr. Donald J. Hillebrand to its Scientific Advisory Board. Dr. Hillebrand is a leading expert in Hepatology and Liver Transplantation. His background includes significant clinical research and contributions to medical literature. Sigyn specializes in treating conditions related to sepsis, utilizing their innovative Sigyn Therapy™ for blood purification that targets pathogen-related inflammation. The company emphasizes the importance of their therapy in addressing severe infectious diseases and liver disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced the appointment of Dr. Ajay Verma to its Scientific Advisory Board. Dr. Verma, a notable figure in neurology, brings extensive clinical experience that is expected to enhance the development of Sigyn Therapy, an extracorporeal blood purification technology aimed at treating life-threatening inflammatory disorders. His previous roles include leading R&D at Yumanity Therapeutics and serving at prominent companies like Biogen and Novartis. Sigyn Therapeutics focuses on addressing sepsis and other severe conditions through innovative medical technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Sigyn Therapeutics (OTC: SIGY) has filed its annual report for the year ended December 31, 2021, highlighting significant advancements in its Sigyn Therapy, a blood purification technology aimed at treating sepsis and inflammatory disorders. The company reported an operating loss of approximately $2.0 million, up from $916,000 in 2020. Additionally, it showcased various milestones, including successful studies demonstrating the therapy's effectiveness against viral pathogens and hepatic toxins. Sigyn plans to submit an Investigational Device Exemption to the FDA for clinical studies, indicating a commitment to advancing its innovative treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Sigyn Therapeutics (SIGY) appointed Dr. H. David Humes, a recognized nephrologist, to its Scientific Advisory Board. Dr. Humes brings extensive expertise in medical technology, especially in overseeing preclinical studies of Sigyn Therapy, a blood purification technology aimed at treating sepsis and related conditions. His contributions are expected to enhance clinical advancements for the therapy, which targets life-threatening inflammatory disorders. With a strong academic background and numerous patents, Dr. Humes is well-positioned to support Sigyn's mission to combat sepsis and other serious health threats.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTC Markets: SIGY) has appointed Dr. Alexander S. Yevzlin to its Scientific Advisory Board. Dr. Yevzlin, a leader in Interventional Nephrology, brings extensive experience from his academic and clinical background to advance Sigyn Therapy, a blood purification technology targeting life-threatening inflammatory disorders, including sepsis. His contributions are expected to aid in the clinical advancement of this innovative therapy. Sigyn Therapy aims to address various critical conditions, enhancing the company's focus on significant health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
management
-
Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced the appointment of Jeremy Ferrell, CPA, MBA, as its new Chief Financial Officer, effective March 9, 2022. With over 25 years of finance and operations leadership experience, Ferrell aims to enhance operational finance and manage investor relations. Previously CFO at Miku, Inc., he has notable experience in the life sciences sector. CEO Jim Joyce expressed confidence in Ferrell's ability to support the advancement of Sigyn Therapy and the pursuit of a major exchange listing, highlighting the importance of his role during this transformative period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
management
-
Rhea-AI Summary

Sigyn Therapeutics announced the successful completion of an in vivo animal study, demonstrating that Sigyn Therapy is safe and well tolerated during six-hour treatments. This novel blood purification technology targets life-threatening inflammatory conditions like sepsis. The study involved administering therapy to eight porcine subjects with stable health parameters and no serious adverse events. The company plans to submit data for an Investigational Device Exemption to the FDA, aiming for human clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
Rhea-AI Summary

Sigyn Therapeutics (OTC Markets: SIGY) announced that its CEO, Jim Joyce, will present at the Bullseye Small Cap Virtual Investor Conference on January 27, 2022, at 3:30 PM Eastern. The presentation will focus on Sigyn Therapy™, a blood purification technology aimed at treating pathogen-related conditions leading to sepsis, a major cause of hospital fatalities. Attendees can register for the event and schedule one-on-one meetings with company management for further discussions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of SIGYN THERAPEUTICS (SIGY)?

The current stock price of SIGYN THERAPEUTICS (SIGY) is $5.25 as of August 22, 2024.

What is the market cap of SIGYN THERAPEUTICS (SIGY)?

The market cap of SIGYN THERAPEUTICS (SIGY) is approximately 7.3M.

What is Sigyn Therapeutics' core business?

Sigyn Therapeutics specializes in developing blood purification technologies to treat pathogen-associated inflammatory disorders that are not effectively addressed by conventional drug therapies.

What are the key products developed by Sigyn Therapeutics?

Key products include Sigyn Therapy™ for inflammatory disorders, ImmunePrep™ for enhancing immunotherapeutic antibodies, ChemoPrep™ for optimizing chemotherapy delivery, and ChemoPure™ for reducing chemotherapy toxicity.

What conditions does Sigyn Therapy™ aim to treat?

Sigyn Therapy™ focuses on treating conditions such as endotoxemia, sepsis, community-acquired pneumonia, and infections caused by drug-resistant bacteria and viruses.

What is the status of Sigyn Therapeutics' clinical trials?

The company is preparing to initiate first-in-human studies of Sigyn Therapy™ in end-stage renal disease (ESRD) patients with endotoxemia.

How is Sigyn Therapeutics performing financially?

For the year ending December 31, 2023, Sigyn reported a net loss of approximately $4.1 million, reflecting its substantial investment in research and development.

What recent strategic financial move did Sigyn Therapeutics make?

Sigyn Therapeutics completed a 1-for-40 reverse stock split to meet Nasdaq listing requirements.

Where is Sigyn Therapeutics headquartered?

Sigyn Therapeutics is headquartered in San Diego, California.

What is the market potential for Sigyn Therapeutics' products?

The potential market for ImmunePrep™ alone is projected to reach $566.72 billion USD by 2032, indicating significant growth opportunities for Sigyn products.

How can investors access more information about Sigyn Therapeutics?

Investors can access detailed financial results and updates on the company's website at www.SigynTherapeutics.com and on the SEC's website at www.sec.gov.

Who should be contacted for more information about Sigyn Therapeutics?

For more information, contact Jim Joyce, Chairman, and CEO, at 619.353.0800 or via email at jj@SigynTherapeutics.com.

SIGYN THERAPEUTICS INC

OTC:SIGY

SIGY Rankings

SIGY Stock Data

7.27M
949.02k
51.94%
7.37%
Biotechnology
Healthcare
Link
United States of America
San Diego